Dr. Schachter speaks with Azura Ophthalmics CEO Marc Gleeson about the company’s pipeline, which is focused on the development of ophthalmic keratolytics for the treatment of disorders affecting the lid margin and ocular surface. The novel approach targets hyperkeratinization and impaired lipid secretory function of […]